Home/Rare Diseases/Friedreich Ataxia

Neurological & Neuromuscular

Friedreich Ataxia

Also called Friedreich's ataxia, FA, FRDA

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by GAA trinucleotide repeat expansion in the FXN gene, which encodes frataxin protein. Frataxin is essential for mitochondrial function and iron homeostasis; when deficient, mitochondrial dysfunction and iron accumulation damage neurons and cardiac muscle.

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Friedreich Ataxia

Clinical trials for FRDA are evaluating frataxin gene replacement therapy, frataxin upregulation strategies (like omaveloxolone), mitochondrial function enhancers, and iron chelation approaches. The Friedreich's Ataxia Research Alliance (FARA) maintains comprehensive trial information and patient resources.

Try Match Me →

About Friedreich Ataxia

Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disorder caused by GAA trinucleotide repeat expansion in the FXN gene, which encodes frataxin protein. Frataxin is essential for mitochondrial function and iron homeostasis; when deficient, mitochondrial dysfunction and iron accumulation damage neurons and cardiac muscle. The disease causes progressive degeneration of the posterior columns and spinocerebellar tracts of the spinal cord, as well as the dorsal root ganglia, resulting in loss of coordination (ataxia), weakness, sensory loss, and speech impairment. Hypertrophic cardiomyopathy develops in 90% of patients and is the primary cause of death. The disease typically begins in late childhood or early adulthood and progresses relentlessly, causing progressive mobility loss, speech and swallowing difficulties, and cardiac dysfunction. Lifespan is typically reduced by 10-15 years, with average life expectancy around age 50.

Common Symptoms

  • Progressive loss of coordination and balance (ataxia)
  • Weakness and spasticity in legs
  • Speech difficulties and difficulty swallowing
  • Loss of sensation in extremities
  • Heart abnormalities and cardiomyopathy
  • Scoliosis and foot deformities

Who It Affects

Symptoms typically begin in late childhood to early adulthood (ages 10-25 years). Affects males and females equally. Usually leads to wheelchair dependence within 15-20 years of symptom onset; lifespan reduced by 10-15 years, with cardiac complications the most common cause of death.

Getting Involved in Clinical Trials

Clinical trials for FRDA are evaluating frataxin gene replacement therapy, frataxin upregulation strategies (like omaveloxolone), mitochondrial function enhancers, and iron chelation approaches. The Friedreich's Ataxia Research Alliance (FARA) maintains comprehensive trial information and patient resources. Early diagnosis through genetic testing is important to allow participation in clinical trials that may slow disease progression. Omaveloxolone, a phase 3 trial drug, has shown promise in slowing neurological decline. Genetic counseling is recommended for affected individuals and families. Multidisciplinary care including neurology, cardiology, and rehabilitation services optimizes outcomes and quality of life.

Trusted Sources

Active Clinical Trials for Friedreich Ataxia

Finding trials for Friedreich Ataxia...

Related Neurological & Neuromuscular Conditions

Neurological & Neuromuscular

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...

Neurological & Neuromuscular

Spinal Muscular Atrophy

Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...

Neurological & Neuromuscular

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...